UPDATE: Oppenheimer Downgrades Rocket Pharmaceuticals (RCKT) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting
December 7, 2020 2:30 PM ESTTwo of Three FA Process B Patients with at Least 12-Months Follow-Up and Three of Four Additional Patients with Shorter Follow-Up Demonstrate Evidence of Engraftment
Follow-Up Data from Phase 1/2 Trial for Leukocyte Adhesion Deficiency-I Demonstrate Durable CD18 Expression
Both Trials on Track and Continue to Support Potential Registration Path Using Process B
NEW YORK--(BUSINESS... More
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meet
December 6, 2020 10:00 AM ESTPreliminary Data from First Patient Demonstrates Initial Safety and Tolerability of RP-L301, Near Doubling of Hemoglobin to Normal Range and Additional Normalization of Hemolysis Markers
Rockets Largest Lentiviral Pipeline Program Aims to Address Unmet Need for up to 8,000 PKD Patients in the U.S. and Europe
NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ:... More
